Jafron BiomedicalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Jafron BiomedicalLtd wird ein jährliches Gewinn- und Umsatzwachstum von 26.1% bzw. 23.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 25.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 27.7% betragen.

Wichtige Informationen

26.1%

Wachstumsrate der Gewinne

25.6%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	26.6%
Wachstumsrate der Einnahmen	23.6%
Zukünftige Eigenkapitalrendite	27.7%
Analystenabdeckung	Low
Zuletzt aktualisiert	24 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Oct 21

Recent updates

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Oct 21

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

Oct 02

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Sep 09

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Aug 25

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

May 28

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

May 24

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

May 08

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

May 02

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Apr 13

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Mar 22

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Mar 04

Gewinn- und Umsatzwachstumsprognosen

SZSE:300529 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	4,486	1,525	N/A	1,488	4
12/31/2025	3,645	1,137	N/A	1,153	4
12/31/2024	2,908	1,083	N/A	1,178	4
9/30/2024	2,632	804	873	1,198	N/A
6/30/2024	2,406	711	926	1,229	N/A
3/31/2024	2,094	525	877	1,185	N/A
12/31/2023	1,922	436	669	917	N/A
9/30/2023	1,952	440	790	949	N/A
6/30/2023	1,949	419	609	872	N/A
3/31/2023	2,367	751	630	995	N/A
1/1/2023	2,491	890	408	884	N/A
9/30/2022	2,919	1,207	589	1,108	N/A
6/30/2022	3,041	1,325	670	1,206	N/A
3/31/2022	2,794	1,249	634	1,143	N/A
1/1/2022	2,675	1,197	712	1,249	N/A
9/30/2021	2,417	1,111	550	1,129	N/A
6/30/2021	2,269	1,055	575	1,110	N/A
3/31/2021	2,151	974	554	1,043	N/A
12/31/2020	1,951	875	600	957	N/A
9/30/2020	1,776	780	441	696	N/A
6/30/2020	1,643	706	431	669	N/A
3/31/2020	1,516	626	421	640	N/A
12/31/2019	1,432	571	363	583	N/A
9/30/2019	1,290	514	319	541	N/A
6/30/2019	1,219	498	236	465	N/A
3/31/2019	1,105	442	215	423	N/A
12/31/2018	1,017	402	211	384	N/A
9/30/2018	925	387	127	321	N/A
6/30/2018	846	345	N/A	317	N/A
3/31/2018	777	315	N/A	308	N/A
12/31/2017	718	284	N/A	304	N/A
9/30/2017	662	266	N/A	293	N/A
6/30/2017	612	251	N/A	283	N/A
3/31/2017	566	215	N/A	205	N/A
12/31/2016	544	202	N/A	179	N/A
9/30/2016	537	204	N/A	182	N/A
6/30/2016	547	209	N/A	192	N/A
3/31/2016	532	210	N/A	195	N/A
12/31/2015	509	200	N/A	205	N/A
12/31/2014	371	160	N/A	137	N/A
12/31/2013	304	127	N/A	133	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 300529Das prognostizierte Gewinnwachstum (26.1% pro Jahr) liegt über der Sparquote (2.8%).

Ertrag vs. Markt: 300529Die Erträge des Unternehmens (26.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (25.9% pro Jahr).

Hohe Wachstumserträge: 300529Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 300529Die Einnahmen des Unternehmens (23.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (13.8% pro Jahr).

Hohe Wachstumseinnahmen: 300529Die Einnahmen des Unternehmens (23.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 300529Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (27.7%)

Jafron BiomedicalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates increase by 34%

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Consensus revenue estimates fall by 13%

Price target decreased to CN¥56.67

Price target decreased to CN¥73.99

Price target raised to CN¥95.66

Recent updates

Now 27% overvalued after recent price rise

Consensus EPS estimates increase by 34%

Earnings Report: Jafron Biomedical Co.,Ltd. Missed Revenue Estimates By 8.1%

Now 22% overvalued after recent price rise

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.18 in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Further Upside For Jafron Biomedical Co.,Ltd. (SZSE:300529) Shares Could Introduce Price Risks After 34% Bounce

New minor risk - Share price stability

Jafron Biomedical Co.,Ltd. to Report Q3, 2024 Results on Oct 19, 2024

Now 20% overvalued after recent price rise

Investor sentiment improves as stock rises 17%

Estimating The Fair Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

The Returns On Capital At Jafron BiomedicalLtd (SZSE:300529) Don't Inspire Confidence

Second quarter 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.10 in 2Q 2023)

Jafron Biomedical Co.,Ltd. to Report First Half, 2024 Results on Aug 08, 2024

Jafron BiomedicalLtd's (SZSE:300529) Dividend Will Be Reduced To CN¥0.40

Dividend reduced to CN¥0.40

A Look At The Intrinsic Value Of Jafron Biomedical Co.,Ltd. (SZSE:300529)

Why Investors Shouldn't Be Surprised By Jafron Biomedical Co.,Ltd.'s (SZSE:300529) 30% Share Price Surge

Now 20% overvalued after recent price rise

Jafron BiomedicalLtd's (SZSE:300529) Soft Earnings Don't Show The Whole Picture

Jafron Biomedical Co.,Ltd., Annual General Meeting, May 20, 2024

Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023

First quarter 2024 earnings released: EPS: CN¥0.35 (vs CN¥0.25 in 1Q 2023)

Investors Could Be Concerned With Jafron BiomedicalLtd's (SZSE:300529) Returns On Capital

Jafron Biomedical Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Does Jafron BiomedicalLtd (SZSE:300529) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 15%

Jafron Biomedical Co.,Ltd.'s (SZSE:300529) P/E Is Still On The Mark Following 31% Share Price Bounce

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2022)

Consensus revenue estimates fall by 13%

Investor sentiment improves as stock rises 16%

Jafron Biomedical Co.,Ltd. to Report Q3, 2023 Results on Oct 30, 2023

New minor risk - Profit margin trend

Second quarter 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.51 in 2Q 2022)

Jafron Biomedical Co.,Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Jafron Biomedical Co.,Ltd. Announces Cash Dividend on A Shares for the Year 2022, Payable on 31 May 2023

High number of new directors

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.30 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.43 in 2Q 2021)

Jafron Biomedical Co.,Ltd. Implements Final Cash Dividend (A Shares) for 2021, Payable on 10 June 2022

Jafron Biomedical Co.,Ltd. Approves Profit Distribution

Price target decreased to CN¥56.67

High number of new and inexperienced directors

Jafron Biomedical Co.,Ltd. Announces the Profit Distribution Proposal for 2021

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to CN¥73.99

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.23 in 3Q 2020)

Jafron Biomedical Co.,Ltd. (SZSE:300529) commences an Equity Buyback Plan for CNY 500 million worth of its shares, under the authorization approved on September 14, 2021.

Second quarter 2021 earnings released: EPS CN¥0.43 (vs CN¥0.32 in 2Q 2020)

Investor sentiment deteriorated over the past week

Jafron Biomedical Co.,Ltd. Announces 2020 Final Profit Distribution, Payable on 12 May 2021

Full year 2020 earnings released: EPS CN¥1.10 (vs CN¥0.73 in FY 2019)

Jafron Biomedical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 01, 2021

New 90-day high: CN¥84.63

New 90-day low: CN¥64.16

Market pulls back on stock over the past week

Price target raised to CN¥95.66

New 90-day high: CN¥78.75

Price target raised to CN¥52.96

Third quarter earnings released